184 related articles for article (PubMed ID: 33649389)
21. Enhancement of antitumor response of staphylococcal enterotoxin C2 mutant 2M-118 by promoting cell-mediated antitumor immunity.
Chen X; Liu Y; Du B; Shi M; Lin Z; Li H; Chen J; Wu M; Shi M
Int Immunopharmacol; 2024 May; 132():111943. PubMed ID: 38581989
[TBL] [Abstract][Full Text] [Related]
22. The Curcumin Analog GO-Y030 Controls the Generation and Stability of Regulatory T Cells.
MaruYama T; Kobayashi S; Nakatsukasa H; Moritoki Y; Taguchi D; Sunagawa Y; Morimoto T; Asao A; Jin W; Owada Y; Ishii N; Iwabuchi Y; Yoshimura A; Chen W; Shibata H
Front Immunol; 2021; 12():687669. PubMed ID: 34248973
[TBL] [Abstract][Full Text] [Related]
23. Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma.
Kalaora S; Wolf Y; Feferman T; Barnea E; Greenstein E; Reshef D; Tirosh I; Reuben A; Patkar S; Levy R; Quinkhardt J; Omokoko T; Qutob N; Golani O; Zhang J; Mao X; Song X; Bernatchez C; Haymaker C; Forget MA; Creasy C; Greenberg P; Carter BW; Cooper ZA; Rosenberg SA; Lotem M; Sahin U; Shakhar G; Ruppin E; Wargo JA; Friedman N; Admon A; Samuels Y
Cancer Discov; 2018 Nov; 8(11):1366-1375. PubMed ID: 30209080
[TBL] [Abstract][Full Text] [Related]
24. Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade.
D'Alise AM; Leoni G; Cotugno G; Troise F; Langone F; Fichera I; De Lucia M; Avalle L; Vitale R; Leuzzi A; Bignone V; Di Matteo E; Tucci FG; Poli V; Lahm A; Catanese MT; Folgori A; Colloca S; Nicosia A; Scarselli E
Nat Commun; 2019 Jun; 10(1):2688. PubMed ID: 31217437
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy with dendritic cells and tumor major histocompatibility complex class I-derived peptides requires a high density of antigen on tumor cells.
Rawson P; Hermans IF; Huck SP; Roberts JM; Pircher H; Ronchese F
Cancer Res; 2000 Aug; 60(16):4493-8. PubMed ID: 10969797
[TBL] [Abstract][Full Text] [Related]
26. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
[TBL] [Abstract][Full Text] [Related]
27. Peptide: MHC-based DNA vaccination strategy to activate natural killer cells by targeting killer cell immunoglobulin-like receptors.
Rettman P; Blunt MD; Fulton RJ; Vallejo AF; Bastidas-Legarda LY; España-Serrano L; Polak ME; Al-Shamkhani A; Retiere C; Khakoo SI
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016721
[TBL] [Abstract][Full Text] [Related]
28. A spontaneous multifunctional hydrogel vaccine amplifies the innate immune response to launch a powerful antitumor adaptive immune response.
Liang X; Li L; Li X; He T; Gong S; Zhu S; Zhang M; Wu Q; Gong C
Theranostics; 2021; 11(14):6936-6949. PubMed ID: 34093863
[TBL] [Abstract][Full Text] [Related]
29. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.
Neeley YC; McDonagh KT; Overwijk WW; Restifo NP; Sanda MG
Prostate; 2002 Nov; 53(3):183-91. PubMed ID: 12386918
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of anti-cancer and immunomodulatory effects of carnosol in a Balb/c WEHI-164 fibrosarcoma model.
Rahnama M; Mahmoudi M; Zamani Taghizadeh Rabe S; Balali-Mood M; Karimi G; Tabasi N; Riahi-Zanjani B
J Immunotoxicol; 2015; 12(3):231-8. PubMed ID: 25027673
[TBL] [Abstract][Full Text] [Related]
31. Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach.
Lu Y; Wang Y; Miao L; Haynes M; Xiang G; Huang L
Cancer Lett; 2016 Aug; 379(1):32-8. PubMed ID: 27235608
[TBL] [Abstract][Full Text] [Related]
32. Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization.
Zhou Q; Xiao H; Liu Y; Peng Y; Hong Y; Yagita H; Chandler P; Munn DH; Mellor A; Fu N; He Y
J Immunol; 2010 Nov; 185(9):5082-92. PubMed ID: 20926790
[TBL] [Abstract][Full Text] [Related]
33. Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors.
Lu S; Zhang J; Liu D; Li G; Staveley-O'Carroll KF; Li Z; Wu JD
Clin Cancer Res; 2015 Nov; 21(21):4819-30. PubMed ID: 26106076
[TBL] [Abstract][Full Text] [Related]
34. Epitope diversification driven by non-tumor epitope-specific Th1 and Th17 mediates potent antitumor reactivity.
Ichikawa K; Kagamu H; Koyama K; Miyabayashi T; Koshio J; Miura S; Watanabe S; Yoshizawa H; Narita I
Vaccine; 2012 Sep; 30(43):6190-7. PubMed ID: 22889826
[TBL] [Abstract][Full Text] [Related]
35. Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A.
Markiewicz MA; Fallarino F; Ashikari A; Gajewski TF
Int Immunol; 2001 May; 13(5):625-32. PubMed ID: 11312250
[TBL] [Abstract][Full Text] [Related]
36. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
37. A minigene DNA vaccine encoding peptide epitopes derived from Galectin-1 has protective antitumoral effects in a model of neuroblastoma.
Liebscher L; Weißenborn C; Langwisch S; Gohlke BO; Preissner R; Rabinovich GA; Christiansen N; Christiansen H; Zenclussen AC; Fest S
Cancer Lett; 2021 Jul; 509():105-114. PubMed ID: 33848518
[TBL] [Abstract][Full Text] [Related]
38. Conjugation of toll-like receptor-7 agonist to gastric cancer antigen MG7-Ag exerts antitumor effects.
Wang XD; Gao NN; Diao YW; Liu Y; Gao D; Li W; Wan YY; Zhong JJ; Jin GY
World J Gastroenterol; 2015 Jul; 21(26):8052-60. PubMed ID: 26185376
[TBL] [Abstract][Full Text] [Related]
39. Thiol dependent NF-κB suppression and inhibition of T-cell mediated adaptive immune responses by a naturally occurring steroidal lactone Withaferin A.
Gambhir L; Checker R; Sharma D; Thoh M; Patil A; Degani M; Gota V; Sandur SK
Toxicol Appl Pharmacol; 2015 Dec; 289(2):297-312. PubMed ID: 26408225
[TBL] [Abstract][Full Text] [Related]
40. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
